S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

Santhera Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:SPHDF)

$13.35
0.00 (0.00%)
(As of 11/28/2023 ET)
Compare
Today's Range
$13.35
$13.35
50-Day Range
$0.68
$13.35
52-Week Range
$9.40
$13.35
Volume
N/A
Average Volume
3,788 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SPHDF stock logo

About Santhera Pharmaceuticals Stock (OTCMKTS:SPHDF)

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

SPHDF Stock Price History

SPHDF Stock News Headlines

US FDA approves Santhera's Duschenne drug
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Santhera Pharmaceuticals reports 1H results
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Santhera Pharmaceuticals GAAP EPS of -CHF1.17
Santhera Publishes Annual Report 2022
See More Headlines
Receive SPHDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SPHDF
CIK
N/A
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Thomas Meier Ph.D. (Age 61)
    Founder & Chairman
    Comp: $94.62k
  • Mr. Dario Eklund (Age 55)
    Chief Executive Officer
    Comp: $920.58k
  • Mr. Andrew P. Smith CGMA (Age 60)
    FCMA, Chief Financial Officer
  • Mr. Oliver Strub (Age 60)
    Executive VP, General Counsel & Secretary
  • Mr. Günther Metz Ph.D. (Age 65)
    Head of Business Development & Executive VP
  • Mr. Shabir Hasham M.D.
    Chief Medical Officer
  • Ms. Stephanie Brown B.Sc. (Age 62)
    M.B.A., President of North America
  • Mr. Marc Schrader
    Head of Technical Development & Operations
  • Ms. Eva Kalias
    Head of Investor Relations & Communications
  • Mr. Neville Kodkani M.D.
    Head of Global Marketing & Partner Management














SPHDF Stock Analysis - Frequently Asked Questions

How have SPHDF shares performed in 2023?

Santhera Pharmaceuticals' stock was trading at $14.10 on January 1st, 2023. Since then, SPHDF shares have decreased by 5.3% and is now trading at $13.35.
View the best growth stocks for 2023 here
.

Are investors shorting Santhera Pharmaceuticals?

Santhera Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 136,400 shares, an increase of 69.0% from the October 15th total of 80,700 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 104.9 days.
View Santhera Pharmaceuticals' Short Interest
.

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SPHDF) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -